查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1853778

新冠病毒检测市场按检测类型、样本类型和最终用户划分－2025-2032年全球预测

COVID-19 Testing Market by Test Type, Sample Type, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，COVID-19 检测市场规模将成长 952 亿美元，复合年增长率为 10.56%。

关键市场统计数据
基准年2024年 426.2亿美元
预计年份：2025年 471.3亿美元
预测年份 2032 952亿美元
复合年增长率 (%) 10.56%

对不断变化的 COVID-19 检测格局进行清晰概述，以明确诊断选择、操作权衡和相关人员的策略决策槓桿。

由于科学进步、公共卫生重点的转变以及全球供应链的变化，新冠病毒检测模式仍在快速演变。本执行摘要摘要诊断方法的技术进步与监管调整、供应弹性以及分散式检查模式的普及等实际操作情况进行了梳理。

相关人员必须权衡检测的临床效能特征与实际考虑因素，例如周转时间、易用性和检体类型相容性。这种平衡将决定检测的采用模式以及最适合特定应用情境（从医院分诊到居家监测）的检测路径。更先进的分子技术的应用和基于抗原的快速检测的标准化，既补充又挑战了传统实验室PCR检测的核心地位，迫使各机构重新思考其工作流程、人员配置模式和投资重点。

最后，引言部分概述了报告着重于可操作资讯的重点。报告着重阐述了能够帮助领导者应对采购复杂性、优化检测组合以及使诊断策略与更广泛的公共卫生和商业性目标一致的洞见。接下来的内容强调实际应用，而非不切实际的推断，从而为在诊断领域不断成熟的过程中做出稳健且基于证据的决策奠定基础。

快速的技术创新、分散式医疗保健路径和灵活的监管如何从根本上改变诊断服务模式和策略重点

技术创新、去中心化和监管灵活性正在以既颠覆又赋能的方式重塑诊断格局，尤其体现在更灵敏、多重化的分子检测和易于操作的快速抗原检测方法上。这些创新催生了一种新的创造性模式：检测不再是中心实验室的专属领域；即时检测和居家检测在早期发现、治疗分诊和社区监测中发挥着越来越重要的作用。

同时，政策转变鼓励加速监管审批流程和采用更灵活的报销机制，加速市场准入，同时也提高了上市后绩效监测的标准。因此，製造商、服务供应商和医疗系统必须建立更具活力的生态系统才能保持竞争力。投资多元化采购、灵活生产和垂直整合试剂管线的公司，更有能力应对突如其来的需求激增或原料短缺。

随着市场格局的演变，能够将产品创新与以用户为中心的部署模式相结合、加强诊断价值链各环节的伙伴关係、并将真实世界的性能反馈融入产品开发的企业，将成为未来的赢家。这项转变要求研发、监管、采购和商业团队通力合作、精心规划，在管控营运风险的同时，掌握新的机会，创造价值。

检验不断变化的贸易政策如何重塑诊断检测生态系统的筹资策略、生产选择和采购惯例。

美国关税调整和贸易政策行动将对新冠病毒检测价值链产生重大影响，进而影响诊断耗材的相对成本、供应和分销。对关键零件征收更高的进口关税可能会增加检测试剂生产商和检测套组组装商的投入成本，从而挤压利润空间或迫使采购商将成本转嫁给消费者。除了影响单价外，关税还可能改变采购策略，促使供应商进行地理多元化，并重新聚焦本地生产能力，以保护诊断必需品免受国际贸易波动的影响。

累积影响也将波及供应链的时序安排和库存策略。为因应关税带来的不确定性，各组织将扩大常用试剂和耗材的安全库存，与一级主导谈判长期合同，并寻找替代零件来源。虽然这些措施可能缓解眼前的供应风险，但也可能导致营运成本需求和仓储成本增加。同时，原料和零件製造商可能会加快投资，将部分生产环节转移到国内或免税地区，并重组其供应商格局和伙伴关係关係。

采购机构和卫生系统的政策应对措施通常是加强支持国内生产，具体措施包括有针对性的优先采购、提前承诺采购以及奖励设施升级。决策者的策略重点是製定灵活的采购框架，检验来自多个管道的供应，并进行基于情境的规划，以因应贸易中断和监管环境的变化。这种准备工作有助于降低营运脆弱性，并在各种贸易制度下维持检测服务的连续性。

主导细分市场，清楚阐明检测方式、检体选择和最终使用者管道如何相互交织，从而决定诊断效用和操作可行性。

对市场区隔的深入理解有助于明确投资和营运改善的重点领域。从检测类型来看，市场涵盖抗体检测、抗原检测和即时PCR检测，其中即时PCR检测又因数位PCR、多重PCR和定量PCR等技术的进步而进一步细分。抗体检测可用于血清阳性率和回顾性暴露分析，抗原检测可实现快速照护现场，而各种PCR检测则可用于诊断确认、病毒量评估和多重病原体检测。

虽然血液检测是获取血清学资讯的常用方法，但样本基质的选择会进一步影响检测方案的製定，因为鼻咽拭子、口咽拭子和唾液样本在灵敏度、患者舒适度和采集物流等方面各有优劣。样本类型的选择会影响临床工作流程、检体运输要求和生物安全通讯协定，因此，根据特定应用情境进行仔细选择至关重要。

诊断实验室强调高通量、高度可控的环境；家庭使用反映了消费者主导的检测和自采集模式的兴起；医院和诊所优先考虑能够指导即时治疗决策的快速诊断结果；而研究机构则致力于检测方法的检验、变异监测和方法创新。了解检测类型与样本类型和最终用户的对应关係，将有助于揭示诊断效用、报销潜力和操作可行性之间的交集，从而使相关人员能够设计出满足临床需求和使用者能力的产品。

区域差异化分析表明，基础设施、监管和製造业优势如何影响全球检测通道的准入和营运策略。

区域动态正在影响新冠病毒检测的取得、应用和运作方式，各主要区域已呈现明显的趋势。在美洲，诊断网络优先考虑规模和容量，透过整合实验室服务和强大的检测能力，支持分子检测和抗原检测平台的广泛部署。法规环境正朝着快速紧急核准和合理的报销安排方向发展，这不仅加速了创新检测方式的推广，也要求强有力的品质保证以维护临床信心。

由于卫生系统成熟度和采购能力的差异，欧洲、中东和非洲的情况各不相同。高所得的欧洲市场拥有严格的法律规范和强大的实验室基础设施，能够进行先进的分子检测和集中定序，从而追踪病毒变异。相反，该地区许多中低收入国家则优先考虑成本效益高的抗原检测和混合检测策略，以扩大检测覆盖范围。跨国合作和多边采购机制在缓解供应不平衡和加速资源匮乏地区获得检测方面可以发挥重要作用。

亚太地区展现出快速创新和製造业实力的频谱。该地区多个经济体拥有强大的试剂、套件和仪器生产能力，既支持国内市场，也支持出口导向供应链。许多区域政策制定者正在推动儘早采用分散式检查模式，并投资于数位整合，以简化报告流程和公共卫生应对措施。综上所述，这些区域差异需要製定量身定制的商业化、监管和供应策略，以反映当地的基础设施、支付模式和公共卫生优先事项。

深入了解竞争定位、伙伴关係和能力投资，这些因素共同造就了诊断创新和供应链可靠性领域的领导者。

新冠病毒检测领域的竞争格局呈现出快速的产品创新、策略伙伴关係以及围绕核心竞争力的整合浪潮。领先企业正投资于兼具强大分析效能、易用性、稳健的供应链网路以及与医疗系统整合的数据报告功能的诊断平台。试剂供应商、仪器製造商和实验室网路之间的合作正在加速新检测方法的上市，并提高分销效率；同时，与物流和低温运输供应商的伙伴关係正在解决「最后一公里」配送难题。

对品质系统和上市后监测的投资已成为维护声誉和遵守监管规定的必然要求，促使企业加强临床检验项目和实际应用性能监测。能够展现出持续可靠的营运能力和透明的检测性能数据的企业更有可能赢得医疗系统和公共机构的采购合约。此外，那些专注于模组化设计以实现检测升级、多重检测能力和数位化连接的企业，能够更好地适应不断涌现的新变体和不断变化的临床需求。

产业参与者的一项策略重点是协调研发、供应链韧性和商业性执行。建立可扩展的製造地、实现供应商多元化以及提供灵活的商业模式（例如订阅测试服务和试剂即服务协议）可以帮助企业与客户建立长期合作关係，并缓解週期性需求波动。

诊断设备製造商和服务供应商可采取的切实可行的策略重点，以建立具有韧性的供应链、模组化产品和以客户为中心的交付模式。

产业领导者应采取多管齐下的策略，并专注于具有韧性的供应链、模组化产品设计和数据驱动的服务交付。优先考虑关键投入来源多元化，并制定包含合格替代供应商和本地生产能力的紧急时应对计画，以降低贸易中断带来的风险。将供应链压力测试纳入日常规划週期，保持对上游供应商网路的可见性，并在瓶颈影响交货之前预先发现并解决它们。

同时，我们将投资于适应性强的产品架构：设计可针对新标靶进行更新、支援多重检测并与数位化彙报系统对接的检测方法和平台。这种适应性将有助于实现面向未来的成本节约，并延长已部署设备的使用寿命。我们将与临床实验室和医疗系统建立伙伴关係关係，共同开发优化集中式和分散式检测部署流程的工作流程，确保在适当的场景下提供适当的检测。

最后，透过调整定价和合约模式以适应客户需求、提供灵活的购买条款以及捆绑分析服务，可以增强商业化能力。加强上市后监测和真实世界证据项目，有助于建立信任并展现持续的业绩表现。将营运韧性、产品敏捷性和以客户为中心的商业性模式结合，产业领导者既可以抓住成长机会，又能保障服务的连续性。

我们的调查方法结合了专家咨询、文件分析和情境测试，旨在提供可靠且以决策为导向的诊断见解。

本研究整合了一手和二手资料，旨在得出专注于实际应用而非推测性预测的见解。一手资料包括与实验室主任、采购负责人和临床营运负责人进行的结构化讨论，以及与供应链经理和产品开发主管进行的针对性访谈。这些讨论得出了关于营运优先事项、产品性能权衡以及压力条件下采购行为的定性评估。

二次分析利用同侪审查文献、监管指导文件和公共卫生机构发布的资料，检验技术性能声明并分析政策动态。透过交叉引用多个资讯来源，可以对关键主题进行三角验证，尤其是在检测灵敏度权衡、不同样本类型性能差异以及应对供应挑战的政策措施等领域。资料解读优先考虑可重复性和透明度，调查方法和资料来源的标准已记录在报告的附录中。

研究采用情境建模方法，对供应链和采购应对政策中断的反应进行压力测试，并进行敏感度分析，探索可能出现的其他结果。调查方法尽可能强调可追溯的证据和专家佐证，以确保研究结果的可靠性，并能为寻求实施诊断策略的决策者提供实际参考。

综合各项结论，重点阐述永续诊断策略、弹性运作以及将数位技术与商业性创新结合以实现长期价值的重要性。

新冠病毒检测生态系统已从紧急应变阶段发展到结构成熟阶段，其特征是技术不断完善、供应链管理策略稳健、监管规范日益完善。现今的诊断策略需要采取平衡的方法，使检测方法的选择与临床需求相符，制定稳健的采购和生产计划，并将实际性能监测纳入生命週期管理。决策者必须持续评估平台能力与实际营运状况的匹配度，确保投资能够支援永续的服务交付，而非仅仅满足短期需求高峰。

展望未来，整合诊断和数位化彙报系统并提供灵活的商业性安排的能力将成为市场领导者的标誌。同样，投资于适应性检测设计和多元化製造地的企业将更有能力应对政策变化和供应链中断。最终，成功迈入下一阶段的检测，取决于临床、商业和营运部门之间的协调规划，并以实证方法和切合实际的风险管理为基础。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 在农村和欠发达地区扩大快速家用抗原检测的使用
  • 整合多重呼吸道病原体检测板，用于同时检测新冠病毒和其他病原体
  • 拓展人工智慧驱动的诊断分析，以最大限度地减少RT-PCR新冠病毒检测中的假阴性结果
  • 大型集会场所对移动式PCR检测车的需求激增，以便提供快速、现场的COVID-19检测结果。
  • 高灵敏度唾液诊断技术的出现，使得在学校进行非侵入性新冠病毒筛检成为可能。
  • 诊断公司与远端医疗平台伙伴关係，实现无缝的远距新冠病毒检测工作流程

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依检测类型分類的 COVID-19 检测市场

  • 抗体检测
  • 抗原检测
  • 即时PCR检测
    • 数位PCR
    • 多重PCR
    • 定量PCR

9. 依样本类型分類的 COVID-19 检测市场

  • 血
  • 鼻咽拭子
  • 口咽拭子
  • 唾液

第十章：按最终用户分類的 COVID-19 检测市场

  • 诊断实验室
  • 家用
  • 医院和诊所
  • 研究机构

第十一章：各地区的 COVID-19 检测市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章：按群体分類的新冠病毒检测市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章：各国新冠病毒检测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • F. Hoffmann-La Roche AG
    • Abbott Laboratories
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Becton, Dickinson and Company
    • QIAGEN NV
    • Hologic, Inc.
    • bioMerieux SA
    • PerkinElmer, Inc.
    • Siemens Healthineers AG
Product Code: MRR-02026C4C986E

The COVID-19 Testing Market is projected to grow by USD 95.20 billion at a CAGR of 10.56% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 42.62 billion
Estimated Year [2025] USD 47.13 billion
Forecast Year [2032] USD 95.20 billion
CAGR (%) 10.56%

An incisive overview of the evolving COVID-19 testing environment that clarifies diagnostic choices, operational trade-offs, and strategic decision levers for stakeholders

The COVID-19 testing environment continues to evolve at pace, shaped by scientific advances, shifting public health priorities, and changes across global supply chains. This executive summary synthesizes the most salient developments that inform decision-making for clinical laboratories, manufacturers, policy makers, and procurement teams. It frames the technical progress in diagnostic modalities alongside operational realities-regulatory adaptation, supply resilience, and the diffusion of decentralized testing models-that together define how testing is delivered and valued in clinical and community settings.

Across settings, stakeholders must weigh the clinical performance characteristics of assays against practical considerations such as turnaround time, ease of use, and sample type compatibility. This balance drives adoption patterns and determines which testing pathways are best suited to specific use cases, from hospital triage to at-home surveillance. The introduction of more refined molecular techniques and the normalization of antigen-based rapid testing have both complemented and contested the central role of traditional laboratory-based PCR, prompting organizations to reassess workflows, staffing models, and investment priorities.

Finally, the introduction outlines how this report focuses on actionable intelligence. It prioritizes insights that help leaders navigate procurement complexity, optimize testing portfolios, and align diagnostic strategies with broader public health and commercial objectives. The content that follows emphasizes practical implications rather than raw estimates, offering a foundation for resilient, evidence-based decision-making as the diagnostic landscape continues to mature.

How rapid technological innovation, decentralized care pathways, and regulatory agility are fundamentally transforming diagnostic delivery models and strategic priorities

Innovation, decentralization, and regulatory flexibility have collectively reshaped the diagnostic landscape in ways that are both disruptive and enabling. Technological advances have expanded the toolkit available to clinicians and consumers, notably through more sensitive and multiplexed molecular assays as well as rapid antigen formats optimized for ease of administration. These innovations have created new operational paradigms: testing is no longer the exclusive domain of centralized laboratories, and point-of-care or at-home testing increasingly contributes to early detection, therapeutics triage, and community surveillance.

Concurrently, policy shifts have encouraged faster regulatory pathways and adaptive reimbursement structures, which accelerates market entry while raising the bar for post-market performance monitoring. The net effect is a more dynamic ecosystem in which manufacturers, service providers, and health systems must iterate rapidly to maintain relevance. Supply chain sophistication has become a strategic differentiator; organizations that invest in diversified sourcing, flexible manufacturing, and vertically integrated reagent pipelines are better positioned to respond to sudden demand surges or material bottlenecks.

As the landscape transforms, the winners will be those that align product innovation with user-centered deployment models, strengthen partnerships across the diagnostic value chain, and embed real-world performance feedback into product development. These shifts require coordinated planning across R&D, regulatory, procurement, and commercial teams to capture value from emerging opportunities while managing operational risk.

Examining how evolving trade measures are reshaping sourcing strategies, manufacturing choices, and procurement practices across the diagnostic testing ecosystem

Tariff changes and trade policy measures in the United States have material implications for the COVID-19 testing value chain, influencing the relative cost, availability, and distribution of diagnostic supplies. Increased import duties on critical components can raise input costs for assay manufacturers and test kit assemblers, which in turn places pressure on margins or necessitates cost pass-throughs for purchasers. Beyond unit cost effects, tariffs alter procurement calculus by incentivizing regional diversification of suppliers and renewed emphasis on local manufacturing capabilities to shield essential diagnostics from international trade volatility.

The cumulative impact extends to supply chain timing and inventory strategies. Organizations respond to tariff-driven uncertainty by expanding safety stocks of high-use reagents and consumables, negotiating longer-term contracts with tier-one suppliers, and qualifying alternative component sources. These responses can mitigate immediate availability risks but also increase working capital requirements and warehousing overhead. Concurrently, raw material and component manufacturers may accelerate investments to move certain stages of production onshore or to tariff-exempt jurisdictions, reshaping supplier landscapes and partnership structures.

Policy reaction from procurement authorities and health systems often includes a greater willingness to support domestic production through targeted procurement preference, advance purchase commitments, or incentives for facility upgrades. For decision-makers, the strategic focus should be on building flexible sourcing frameworks, validating multi-sourced supply streams, and engaging in scenario-based planning that anticipates both trade disruptions and shifting regulatory conditions. Such preparedness reduces operational fragility and preserves continuity of testing services under varied trade regimes.

Segment-driven clarity on how test modalities, specimen choices, and end-user channels intersect to determine diagnostic utility and operational feasibility

A nuanced understanding of segmentation informs where investments and operational enhancements deliver the greatest impact. When viewed through the lens of test type, the market spans antibody testing, antigen testing, and Real Time PCR testing, with Real Time PCR further differentiated by advances such as Digital PCR, Multiplex PCR, and Quantitative PCR. Each modality carries distinct performance and operational profiles: antibody assays support seroprevalence and retrospective exposure analyses, antigen tests enable rapid point-of-care screening, and the various forms of PCR serve diagnostic confirmation, viral load assessment, and multiplexed pathogen detection.

Sample matrix selection further refines deployment decisions, as blood-based assays are typically leveraged for serological insights while nasopharyngeal swabs, oropharyngeal swabs, and saliva each present trade-offs between sensitivity, patient comfort, and collection logistics. The choice of sample type influences clinical workflows, specimen transport requirements, and biosafety protocols, and therefore merits careful alignment with intended use cases.

End-user channels complete the segmentation picture: diagnostic laboratories focus on high-throughput, highly controlled environments; home use reflects the rise of consumer-directed testing and self-collection models; hospitals and clinics prioritize rapid diagnostic turnarounds that inform immediate care decisions; and research institutes drive assay validation, variant surveillance, and methodological innovation. Understanding how test types map to sample types and end users clarifies where diagnostic utility, reimbursement potential, and operational feasibility converge, enabling stakeholders to design offerings that match clinical demands and user capabilities.

A regionally differentiated analysis showing how infrastructure, regulation, and manufacturing strengths shape testing access and operational strategies across global corridors

Regional dynamics shape access, adoption, and operational approaches to COVID-19 testing, with distinct trends emerging across major geographies. In the Americas, diagnostic networks emphasize scale and throughput, with consolidated laboratory services and substantial testing capacity that supports wide deployment of both molecular and antigen platforms. The regulatory environment tends to favor rapid emergency authorizations and pragmatic reimbursement arrangements, which accelerates adoption of innovative testing formats while also necessitating robust quality assurance to maintain clinical reliability.

In Europe, Middle East & Africa, diverse health system maturity levels and procurement capacities lead to a heterogeneous landscape. High-income European markets combine stringent regulatory oversight with strong laboratory infrastructure, enabling advanced molecular applications and centralized sequencing for variant tracking. Conversely, many middle- and low-income countries within the broader region prioritize cost-effective antigen testing and pooled testing strategies to expand coverage. Cross-border collaboration and multilateral procurement mechanisms play an important role in smoothing supply imbalances and accelerating access in resource-constrained settings.

Asia-Pacific presents a spectrum of rapid innovation and manufacturing strength. Several economies in the region possess significant production capacity for reagents, kits, and instrumentation, which supports export-oriented supply chains as well as domestic deployment. Policymakers in many jurisdictions have promoted early adoption of decentralized testing models and invested in digital integration to streamline reporting and public health responses. Taken together, regional nuances demand tailored commercialization, regulatory, and supply strategies that reflect local infrastructure, payer models, and public health priorities.

Insights into competitive positioning, partnership architectures, and capability investments that define leaders in diagnostic innovation and supply reliability

Competitive dynamics within the COVID-19 testing sector are characterized by rapid product innovation, strategic partnerships, and a wave of consolidation around core capabilities. Leading organizations are investing in diagnostics platforms that combine strong analytical performance with ease of use, robust supply networks, and integrated data reporting to health systems. Collaboration between reagent suppliers, instrument manufacturers, and laboratory networks accelerates time-to-market for new assays and enhances distribution efficiency, while partnerships with logistics and cold-chain providers address last-mile delivery challenges.

Investment in quality systems and post-market surveillance has become a reputational and regulatory imperative, prompting companies to strengthen clinical validation programs and real-world performance monitoring. Firms that demonstrate consistent operational reliability and transparent data on test performance are more successful at securing procurement contracts with healthcare systems and public agencies. Additionally, firms focused on modularity-enabling assay upgrades, multiplexing capabilities, and digital connectivity-are better positioned to adapt to variant emergence and evolving clinical needs.

For industry participants, the strategic priority is to align R&D, supply chain resilience, and commercial execution. Building scalable manufacturing footprints, diversifying supplier bases, and offering flexible commercial models such as subscription testing services or reagent-as-a-service agreements help firms capture long-term relationships with customers and mitigate cyclical demand fluctuations.

Actionable strategic priorities for diagnostic manufacturers and service providers to build resilient supply chains, modular products, and customer-centric delivery models

Industry leaders should adopt a multi-dimensional strategy that emphasizes resilient supply chains, modular product design, and data-enabled service offerings. Prioritize diversification of critical input sources and develop contingency plans that include qualified alternative suppliers and localized production capacity to reduce exposure to trade disruptions. Integrate supply chain stress testing into routine planning cycles and maintain visibility across the upstream supplier network to anticipate bottlenecks before they impact delivery.

In parallel, invest in product architectures that are adaptable-design assays and platforms that can be updated for new targets, support multiplexing, and interface with digital reporting systems. This adaptability lowers the cost of future-proofing and increases the lifespan of deployed instruments. Embrace partnerships with clinical laboratories and health systems to co-develop workflows that optimize test placement between centralized and decentralized settings, ensuring the right test is delivered in the right context.

Finally, enhance commercialization by aligning pricing and contracting models with customer needs, offering flexible purchasing terms, and bundling analytic services. Strengthen post-market surveillance and real-world evidence programs to build trust and demonstrate sustained performance. By combining operational resilience with product agility and customer-centric commercial approaches, industry leaders can capture growth opportunities while safeguarding service continuity.

Methodological approach combining expert consultation, documentary analysis, and scenario testing to produce robust, decision-oriented diagnostic insights

This research synthesizes primary and secondary intelligence to produce insights that emphasize practical implications over speculative projections. Primary inputs included structured consultations with laboratory directors, procurement officers, and clinical affairs leaders, together with targeted interviews of supply chain managers and product development executives. These discussions informed qualitative assessments of operational priorities, product performance trade-offs, and procurement behaviors under stress conditions.

Secondary analysis drew upon peer-reviewed literature, regulatory guidance documents, and public health agency releases to validate technical performance claims and to contextualize policy dynamics. Cross-referencing multiple sources enabled triangulation of key themes, particularly in areas such as assay sensitivity trade-offs, sample type performance nuances, and policy responses to supply challenges. Data interpretation prioritized reproducibility and transparency, with methodological notes and criteria for source inclusion documented in the full report annex.

The study used scenario-based modeling to stress test supply chain and procurement responses to policy disruptions, with sensitivity analyses that explore plausible alternative outcomes. Wherever possible, the methodology emphasized traceable evidence and expert corroboration to ensure findings are robust and practically relevant for decision-makers seeking to operationalize diagnostic strategies.

Concluding synthesis emphasizing sustainable diagnostic strategies, resilient operations, and the integration of digital and commercial innovations for long-term value

The COVID-19 testing ecosystem has moved from emergency improvisation to structured maturation, defined by technological refinement, strategic supply chain management, and evolving regulatory norms. Diagnostic strategies now require a balanced approach that matches assay selection to clinical purpose, incorporates resilient sourcing and manufacturing planning, and embeds real-world performance monitoring into lifecycle management. Decision-makers must continually reassess the alignment between platform capabilities and operational realities, ensuring that investments support sustainable service delivery rather than short-term demand spikes.

Looking ahead, the capacity to integrate diagnostics with digital reporting systems and to offer flexible commercial arrangements will distinguish market leaders. Likewise, organizations that invest in adaptable assay designs and diversified manufacturing footprints will be better positioned to manage policy changes and supply interruptions. Ultimately, successful navigation of the next phase of the testing landscape will depend on coordinated planning across clinical, commercial, and operational functions, underpinned by evidence-based approaches and pragmatic risk management.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of at-home rapid antigen test adoption among rural and underserved communities
  • 5.2. Integration of multiplex respiratory panels for simultaneous detection of COVID-19 and other pathogens
  • 5.3. Scaling of AI-driven diagnostic analytics to minimize false negatives in RT-PCR COVID-19 assays
  • 5.4. Surge in demand for mobile PCR testing units providing rapid on-site COVID-19 results at mass gatherings
  • 5.5. Emergence of high-sensitivity saliva-based diagnostics enabling non-invasive COVID-19 screening in schools
  • 5.6. Partnerships between diagnostic companies and telehealth platforms driving seamless remote COVID-19 testing workflows
  • 5.7. Introduction of CRISPR-based point-of-care assays offering sub-30-minute COVID-19 variant identification in clinics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. COVID-19 Testing Market, by Test Type

  • 8.1. Antibody Test
  • 8.2. Antigen Test
  • 8.3. Real Time Pcr Test
    • 8.3.1. Digital Pcr
    • 8.3.2. Multiplex Pcr
    • 8.3.3. Quantitative Pcr

9. COVID-19 Testing Market, by Sample Type

  • 9.1. Blood
  • 9.2. Nasopharyngeal Swab
  • 9.3. Oropharyngeal Swab
  • 9.4. Saliva

10. COVID-19 Testing Market, by End User

  • 10.1. Diagnostic Laboratories
  • 10.2. Home Use
  • 10.3. Hospitals And Clinics
  • 10.4. Research Institutes

11. COVID-19 Testing Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. COVID-19 Testing Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. COVID-19 Testing Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. F. Hoffmann-La Roche AG
    • 14.3.2. Abbott Laboratories
    • 14.3.3. Thermo Fisher Scientific Inc.
    • 14.3.4. Danaher Corporation
    • 14.3.5. Becton, Dickinson and Company
    • 14.3.6. QIAGEN N.V.
    • 14.3.7. Hologic, Inc.
    • 14.3.8. bioMerieux SA
    • 14.3.9. PerkinElmer, Inc.
    • 14.3.10. Siemens Healthineers AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL COVID-19 TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COVID-19 TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL COVID-19 TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COVID-19 TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS COVID-19 TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL COVID-19 TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. COVID-19 TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. COVID-19 TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. COVID-19 TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL COVID-19 TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL COVID-19 TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIBODY TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIBODY TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIBODY TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIBODY TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIBODY TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIBODY TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIGEN TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIGEN TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIGEN TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIGEN TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIGEN TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIGEN TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL COVID-19 TESTING MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL COVID-19 TESTING MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL COVID-19 TESTING MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL COVID-19 TESTING MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL COVID-19 TESTING MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL COVID-19 TESTING MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL COVID-19 TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL COVID-19 TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL COVID-19 TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL COVID-19 TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL COVID-19 TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL COVID-19 TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL COVID-19 TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL COVID-19 TESTING MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL COVID-19 TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL COVID-19 TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL COVID-19 TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL COVID-19 TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL COVID-19 TESTING MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL COVID-19 TESTING MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL COVID-19 TESTING MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL COVID-19 TESTING MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL COVID-19 TESTING MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL COVID-19 TESTING MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL COVID-19 TESTING MARKET SIZE, BY OROPHARYNGEAL SWAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL COVID-19 TESTING MARKET SIZE, BY OROPHARYNGEAL SWAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL COVID-19 TESTING MARKET SIZE, BY OROPHARYNGEAL SWAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL COVID-19 TESTING MARKET SIZE, BY OROPHARYNGEAL SWAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL COVID-19 TESTING MARKET SIZE, BY OROPHARYNGEAL SWAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL COVID-19 TESTING MARKET SIZE, BY OROPHARYNGEAL SWAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL COVID-19 TESTING MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL COVID-19 TESTING MARKET SIZE, BY SALIVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL COVID-19 TESTING MARKET SIZE, BY SALIVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL COVID-19 TESTING MARKET SIZE, BY SALIVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL COVID-19 TESTING MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL COVID-19 TESTING MARKET SIZE, BY SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOME USE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOME USE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOME USE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOME USE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOME USE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOME USE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL COVID-19 TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL COVID-19 TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL COVID-19 TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL COVID-19 TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL COVID-19 TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL COVID-19 TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL COVID-19 TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL COVID-19 TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. AMERICAS COVID-19 TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS COVID-19 TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 101. AMERICAS COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 103. AMERICAS COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 105. AMERICAS COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 107. AMERICAS COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 114. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 118. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 122. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 124. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 139. EUROPE COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. EUROPE COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. EUROPE COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 143. EUROPE COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPE COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPE COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 154. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. AFRICA COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. AFRICA COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. AFRICA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. AFRICA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. AFRICA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 164. AFRICA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 165. AFRICA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. AFRICA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 167. AFRICA COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. AFRICA COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL COVID-19 TESTING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL COVID-19 TESTING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. ASEAN COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. ASEAN COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. ASEAN COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. ASEAN COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. ASEAN COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 186. ASEAN COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 187. ASEAN COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. ASEAN COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. ASEAN COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. ASEAN COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. GCC COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GCC COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GCC COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. GCC COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. GCC COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 196. GCC COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 197. GCC COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. GCC COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. GCC COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. GCC COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. BRICS COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. BRICS COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. BRICS COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. BRICS COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. BRICS COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 216. BRICS COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 217. BRICS COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. BRICS COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. BRICS COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. BRICS COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. G7 COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. G7 COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. G7 COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. G7 COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. G7 COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 226. G7 COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 227. G7 COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. G7 COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. G7 COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. G7 COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. NATO COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. NATO COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. NATO COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. NATO COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. NATO COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 236. NATO COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 237. NATO COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. NATO COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. NATO COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. NATO COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. UNITED STATES COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. UNITED STATES COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. UNITED STATES COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 246. UNITED STATES COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 247. UNITED STATES COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. UNITED STATES COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. UNITED STATES COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED STATES COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. CANADA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. CANADA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. CANADA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 254. CANADA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 255. CANADA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. CANADA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. CANADA COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. CANADA COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. MEXICO COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. MEXICO COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. MEXICO COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 262. MEXICO COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 263. MEXICO COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. MEXICO COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. MEXICO COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. MEXICO COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. BRAZIL COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. BRAZIL COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. BRAZIL COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 270. BRAZIL COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 271. BRAZIL COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. BRAZIL COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. BRAZIL COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. BRAZIL COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. UNITED KINGDOM COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. UNITED KINGDOM COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. UNITED KINGDOM COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 278. UNITED KINGDOM COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 279. UNITED KINGDOM COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. UNITED KINGDOM COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. UNITED KINGDOM COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. UNITED KINGDOM COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. GERMANY COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. GERMANY COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. GERMANY COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 286. GERMANY COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 287. GERMANY COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. GERMANY COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. GERMANY COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. GERMANY COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. FRANCE COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. FRANCE COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. FRANCE COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 294. FRANCE COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 295. FRANCE COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. FRANCE COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. FRANCE COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. FRANCE COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. RUSSIA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. RUSSIA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. RUSSIA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 302. RUSSIA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 303. RUSSIA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. RUSSIA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. RUSSIA COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. RUSSIA COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 307. ITALY COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. ITALY COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. ITALY COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 310. ITALY COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 311. ITALY COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. ITALY COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 313. ITALY COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 314. ITALY COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 315. SPAIN COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. SPAIN COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. SPAIN COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 318. SPAIN COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 319. SPAIN COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. SPAIN COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. SPAIN COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 322. SPAIN COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 323. CHINA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. CHINA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. CHINA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 326. CHINA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 327. CHINA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. CHINA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. CHINA COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. CHINA COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. INDIA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 332. INDIA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 333. INDIA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 334. INDIA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 335. INDIA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. INDIA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. INDIA COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 338. INDIA COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 339. JAPAN COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 340. JAPAN COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 341. JAPAN COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 342. JAPAN COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 343. JAPAN COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 344. JAPAN COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 345. JAPAN COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 346. JAPAN COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 347. AUSTRALIA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 348. AUSTRALIA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 349. AUSTRALIA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 350. AUSTRALIA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 351. AUSTRALIA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 352. AUSTRALIA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 353. AUSTRALIA COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 354. AUSTRALIA COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 355. SOUTH KOREA COVID-19 TESTING MARKET